MedTrace Logo

Dacarbazine and Carmustine in Metastatic Melanoma

NCT01692691 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2018-04-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether dacarbazine and carmustine at the doses and schedule used in this study will help to increase tumor shrinkage.

Conditions

  • Melanoma Metastatic

Interventions

DRUG

Dacarbazine

Dacarbazine IV - Day 1

DRUG

Carmustine

Carmustine IV- Day 2

DRUG

Neulasta

Neulasta SC - Day 3

Sponsors & Collaborators

  • Western Regional Medical Center

    lead OTHER

Principal Investigators

  • Jordan Waypa, FNP · CTCA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01692691 on ClinicalTrials.gov